Abstract
Patients with lung carcinoma can benefit in several ways from radionuclide studies (Table 1). The major role of the studies is to detect the presence or extent of the primary disease, but newer applications also are having an impact on determinations of prognosis and evaluation of therapy. The various scintigraphic approaches include direct evaluation of pulmonary ventilation and perfusion via the lung scan; evaluation of metastatic disease and opportunistic infections by gallium citrate (67Ga) scintigraphy; evaluation for distant metastases by liver, bone, brain, or other organ scans; and additional applications, such as localization of hemoptysis by technetium 99m (99mTc) red blood cell lung imaging or evaluation of cardiac function by gated blood pool studies in patients receiving certain types of cardiotoxic chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
